

Publikationsliste

Originalpublikationen

1. Krayenbuehl PA, Wiesli P, Maly FE, Vetter W, Schulthess G. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. *Atherosclerosis* 2005;179:103-10.
2. Krayenbuehl PA, Walczyk T, Schoenberg R, von Blanckenburg F, Schulthess G. Hereditary hemochromatosis is reflected in the iron isotope composition of blood. *Blood* 2005;105:3812-6.
3. Krayenbuehl PA, Maly FE, Hersberger M, Wiesli P, Himmelmann A, Eid K, Greminger P, Vetter W, Schulthess G. Tumor necrosis factor-alpha -308G>A allelic variant modulates iron accumulation in patients with hereditary hemochromatosis. *Clin Chem* 2006;52:1552-8.
4. Schulthess G, Wiesli P, Krayenbuehl PA. Chlamydia pneumoniae, harmful only for peripheral arteries? *Int J Cardiol* 2006;112:249-50 (original research results presented in a letter to the editor).
5. Wiesli P, Lehmann R, Krayenbuehl PA, Schmid C, Spinass GA. Assessment of Basal Insulin Requirement Using Fasting Tests in Insulin-treated Patients with Type 2 Diabetes Mellitus. *Exp Clin Endocrinol Diabetes* 2006;114:539-43.
6. Schmid C, Zwimpfer C, Brandle M, Krayenbuehl PA, Zapf J, Wiesli P. Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. *Clin Endocrinol* 2006;65:706-11.
7. Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter W, Schulthess G. TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. *Exp Clin Endocrinol Diabetes* 2007;115:322-6.
8. Wiesli P, Krayenbuehl PA, Kerwer O, Seifert B, Schmid C. Maintenance of glucose control in patients with type 1 diabetes during acute mental stress by riding high-speed rollercoasters. *Diabetes Care* 2007;30:1599-601.
9. Schmid C*, Krayenbuehl PA *, Bernays RL, Zwimpfer C, Maly FE, Wiesli P. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. *Clin Chem* 2007;53:1484-8. (*equal contribution).
10. Krayenbuehl PA, Wiesli P, Schmid C, Lehmann R, Spinass G, Berneis K. Insulin sensitivity in type 2 diabetes is closely associated with LDL particle size. *Swiss Med Wkly* 2008;138:275-80.
11. Rizzo M, Krayenbuehl P, Pernice V, Frasher A, Battista Rini G, Berneis K. LDL size and subclasses in patients with abdominal aortic aneurysm. *Int J Cardiol* 2009;134:406-8.

12. Wiesli P, Krayenbuehl P, Uthoff H, Seifert B, Schmid C. Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes. *Diabetologia* 2009;52:1816-9.
13. Krayenbuehl PA, Hersberger M, Truninger K, Müllhaupt B, Maly FE, Bargetzi M, Schulthess G. Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. *Eur J Gastroenterol Hepatol* 2010;22:835-41.
14. Schwarz P, Strnad P, von Figura G, Janetzko A, Krayenbuehl PA, Adler G, Kulaksiz H. A novel monoclonal antibody immunoassay for the detection of human serum hepcidin. *J Gastroenterol* 2011;46(5):648-56.
15. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in non-anemic, premenopausal women with low serum ferritin concentration. *Blood* 2011;118(12):3222-7.
16. Hotz K, Krayenbuehl PA, Walczyk T. Mobilization of storage iron is reflected in the iron isotopic composition of blood in humans. *J Biol Inorg Chem* 2012;17(2):301-9.
17. Trieß C, von Figura G, Stuhmann M, Butzeck B, Krayenbuehl PA, Strnad P, Kulaksiz H. Diagnosis of hereditary hemochromatosis in the era of genetic testing. *Dig Dis Sci* 2012; 57(11):2988-94.
18. Goetze O, Schmitt J, Spliethoff K, Theurl I, Weiss G, Swinkels DW, Tjalsma H, Maggiorini M, Krayenbühl P, Rau M, Wojtal K, Müllhaupt B, Fried M, Gassmann M, Lutz T, Geier A. Adaptation of iron transport and metabolism to acute high altitude hypoxia in mountaineers. *Hepatology* 2013;58(6):2153-62.
19. Cippà PE, Boucsein I, Adams H, Krayenbuehl PA. Estimating iron overload in patients with suspected liver disease and elevated serum ferritin. *Am J Med.* 2014;127(10):1011.
20. Muskalla AM, Suter PM, Saur M, Nowak A, Hersberger M, Krayenbuehl PA. G-protein receptor kinase 4 polymorphism and response to antihypertensive therapy. *Clin Chem* 2014;60(12):1543-8.
21. Stähli BE, Yonekawa K, Altwegg LA, Wyss C, Hof D, Fischbacher P, Brauchlin A, Schulthess G, Krayenbühl PA, von Eckardstein A, Hersberger M, Neidhart M, Gay S, Novopashenny I, Wolters R, Frank M, Wischnewsky MB, Lüscher TF, Maier W. Clinical criteria replenish high-sensitive troponin and inflammatory markers in the stratification of patients with suspected acute coronary syndrome. *PLoS One.* 2014;9(6):e98626.
22. Reidt S, Namdar M, Serra A, Krayenbühl PA, Gruner C, Keller DI, Lüscher TF, Schried C. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha. *Intern Med J* 2014;44(2):205-7.
23. Nowak A, Artunc F, Serra AL, Pollock E, Krayenbühl PA, Müller C, Friedrich B. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients? *Kidney Blood Press Res* 2015;40(3):266-76.

24. Barbey F, Joly D, Noel E, Drouineau O, Krayenbühl PA, Lidove O. Fabry disease in a geriatric population. *Clin Genet* 2015;88(5):499-501.
25. Franzen D, Gerard N, Bratton DJ, Wons A, Gaisl T, Sievi NA, Clarenbach CF, Kohler M, Krayenbühl PA. Prevalence and Risk Factors of Sleep Disordered Breathing in Fabry disease: A Prospective Cohort Study. *Medicine* 2015;94(52):e2413.
26. Nowak A, Boesch L, Andres E, Battegay E, Hornemann T, Schmid C, Bischoff-Ferrari HA, Suter PM, Krayenbuehl PA. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. *Medicine* 2016;95(52):e5353.
27. Siegenthaler M, Huynh-Do U, Krayenbuehl P, Pollock E, Widmer U, Debaix H, Olinger E, Frank M, Namdar M, Ruschitzka F, Nowak A. Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. *Int J Cardiol* 2017;249:261-267.
28. Franzen DP, Nowak A, Haile SR, Mottet D, Bonani M, Dormond O, Kohler M, Krayenbuehl PA, Barbey F. Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study. *PLoS One* 2017;12(7):e0180437.
29. Menghini M, Prünke C, Krayenbuehl PA, Nowak A. Assessment of drusen and other retinal degenerative changes in patients with hereditary hemochromatosis. *Retina* 2018 Mar;38(3):594-599.
30. Nowak A, Giger R, Krayenbuehl PA. Higher age at diagnosis of Hemochromatosis is the strongest predictor of the occurrence of Hepatocellular Carcinoma in the Swiss Hemochromatosis Cohort: a prospective longitudinal observational study. *Medicine* 2018; 97(42):e12886.
31. Nowak A, Huynh-Do U, Krayenbuehl PA, Beuschlein F, Schiffmann R, Barbey F. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort. *J Inherit Metab Dis* 2020;43(2):326-333.
32. Koelmel S, Nowak A, Krayenbuehl PA. Iron overload associated symptoms and laboratory changes in the Swiss Hemochromatosis Cohort – When a clinician should become attentive. *Swiss Med Wkly* 2020;150:w2029.

Contribution as coinvestigator and member of the AEGIS Study Group

1. Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Büning C, Howaldt S, Stallmach A; AEGIS Study Group. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. *Inflamm Bowel Dis* 2015;21(3):579-88.
2. Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. *Aliment Pharmacol Ther* 2016;44(3):259-70.

Letters

1. Krayenbuehl PA, Wiesli P, Meier T, Schulthess G. Effect of macrolides on peripheral arterial disease depends on patient selection and adequate treatment. *Eur J Vasc Endovasc Surg* 2005;30:334-5.
2. Schmid C, Krayenbühl P, Wiesli P. Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes. *Diabetologia* 2009;52:2668-9.
3. Burkhart A, Krayenbühl P, Suter P. Vitamin-B12 deficiency. *Praxis (Bern 1994)*. 2010;99(7):411-412.
4. Krayenbuehl PA, Heinrich H. One iron pill a day keeps fatigue away? *Evid Based Med*. 2012 Nov 17.
5. Cippà PE, Krayenbuehl PA. Increased height in HFE hemochromatosis. *N Engl J Med* 2013; 369(8):785-6. (original research data presented in a letter to the editor)
6. Krayenbuehl PA, Heinrich H. One iron pill a day keeps fatigue away? *Evid Based Med*. 2013 Aug;18(4):e31.

Case reports

1. Krayenbuehl PA, Christen ST. Tricyclic Antidepressant Overdose Mimicking Myocardial Infarction. *J Clin Basic Cardiol* 2002; 5:197.
2. van der Hoef M, Capaul R, Krayenbühl P, Steurer-Stey C, Schulthess G. Insidious aspects of small pulmonary coin lesions. *Praxis*;92:1087-91.
3. Vilan A, Furrer J, Krayenbühl P, Schulthess G. Emergency landing due to a passenger with chest pain, dyspnea, and vomiting. *Praxis* 2004;93:1150-3.
4. Grob U, Lachat M, Pfammatter T, Krayenbühl P, Kaser L, Schulthess G. Subacute thoracic pain. *Praxis* 2004;93:1197-201.
5. Meyer-Heim T, Krayenbuehl PA, Widmer U. Sore throat, arthralgia, fever and rash. *Praxis* 2006;6:275-55.
6. Schultze D, Mani B, Dollenmaier G, Sahli R, Zbinden A, Krayenbühl PA. Acute Hepatitis E Virus infection with coincident reactivation of Epstein-Barr virus infection in an immunosuppressed patient with rheumatoid arthritis: a case report. *BMC Infect Dis*. 2015;15:474.

Reviews

1. Kolyvanos NU, Krayenbühl PA, Kaser L, Vetter W. Microcytosis/microcytic anemia. Main symptoms: unspecific anemia, symptoms of basic diseases. *Praxis* 2005;94:1191-7.

2. Krayenbühl PA, Naumann KU, Kaser L, Vetter W. Acute intermittent porphyria. Praxis 2006;95:701-7.
3. Naumann UK, Krayenbühl PA, Schulthess G, Kaser L, Vetter W. Infectious mononucleosis (primary infection with Epstein-Barr virus). Praxis 2006;95:525-31.
4. Naumann UK, Krayenbühl PA, Steurer-Stey C, Kaser L, Vetter W. Churg-Strauss syndrome. Main symptoms: asthma, eosinophilia, vasculitis symptoms (especially mononeuritis multiplex). Praxis 2006;95:2003-10.
5. Naumann UK, Krayenbühl PA, Kaser L, Vetter W. Chronic peri-aortitis: retroperitoneal fibrosis (Ormond disease), inflammatory abdominal aortic aneurysm and peri-aneurysmic retroperitoneal fibrosis. Praxis 2007;96:271-7.
6. Krayenbühl PA, Naumann KU, Käser L, Vetter W. Iron deficiency anemia in adults. Main symptoms: fatigue, pallor, (stress-) dyspnea, headache, concentration disorders. Praxis 2007;96:1241-7.
7. Krayenbühl P, Naumann UK, Käser L, Vetter W. Hemochromatosis (hereditary, "primary" hemochromatosis). Praxis 2007;96:2029-35.
8. Kohler S, Schmid C, Krayenbühl PA. Hypercalcemia. Praxis 2009;98:233-40.
9. Baumann K, Krayenbühl P. Fatigue. Praxis 2009;98:465-71.
10. Andres M, Krayenbühl PA, Schwarz U. Differential involuntary muscle movement diagnosis. Praxis 2009;98:985-94.
11. Fehr J, Favrat B, Schleiffenbaum B, Krayenbühl PA, Kapanci C, von Orelli F. Diagnosis and treatment of iron deficiency without anaemia. Praxis 2009;98:1445-51.
12. Burkhart A, Krayenbühl P, Suter P. Vitamin B 12 deficiency. Praxis 2010;99:5-11.
13. Krayenbühl P. Erhöhte Serumferritinwerte: Ursachen und Differentialdiagnose. HAUSARZT PRAXIS 2011;9:4-5.
14. Krayenbühl P. Eisenmangel ohne Anämie: Realität oder Utopie. HAUSARZT PRAXIS 2011; 10-11:40-42.
15. Haller S, Krayenbühl P, Gubler C. Blut ab ano. Praxis 2012;101(1):3-11.
16. Krayenbühl P. Eisenstoffwechsel bei rheumatischen Entzündungsanämien. Rheuma-Schweiz 2012;1:22-25.
17. Franzen D, Krayenbühl PA, Lidove O, Aubert JD, Barbey F. Pulmonary involvement in Fabry disease: Overview and perspectives. Eur J Intern Med. 2013;24(8):707-13.
18. Heinrich H, Kullak-Ublick GA, Krayenbühl PA. Living donor liver donation - primum nihil nocere? Praxis (Bern 1994). 2013;102(21):1277-83.

19. Krayenbühl P. Eisenmangel ohne Anämie –Wissenswertes für den Hausarzt. Leading Opinion 2013, Ausgabe 1/13, Seite 80-83.

20. Franzen D, Krayenbuehl PA, Lidove O, Aubert JD, Barbey F. Pulmonary involvement in Fabry disease: overview and perspectives. Eur J Intern Med. 2013;24(8):707-13.

21. Schweizer S, Krayenbühl PA. The Birt-Hogg-Dube Syndrome. Praxis (Bern 1994). 2014;103(23):1359-66.

22. Schreiner F, Krayenbühl PA, Goede J, Nowak A. Approach to the Patient with Elevated Serum Ferritin. Praxis (Bern 1994) 2016;105(10):543-51.

Angeleitene Dissertationen

1. Irene Boucsein (Universität Zürich 2015)

Estimating iron overload in patients with suspected liver disease and elevated serum ferritin.

2. Anna Muskalla (Universität Zürich 2015)

G-protein receptor kinase 4 polymorphism and response to antihypertensive therapy.

3. Rebekka Giger (Universität Zürich 2016)

Higher age at diagnosis of Hemochromatosis is the strongest predictor of the occurrence of Hepatocellular Carcinoma in the Swiss Hemochromatosis Cohort: a prospective longitudinal observational study.

6.11.2020